HMM302 - Innovations in Medical Biotechnology

Unit details

Note: You are seeing the 2022 view of this unit information. These details may no longer be current. [Go to the current version]
Year:

2022 unit information

Important Update:

Unit delivery will be in line with the most current COVIDSafe health guidelines. We continue to tailor learning experiences for each unit to achieve the best possible mix of online and on-campus activities that successfully blend our approaches to learning, working and research. Please check your unit sites for announcements and updates.

Last updated: 4 March 2022

Enrolment modes:Trimester 1: Burwood (Melbourne), Waurn Ponds (Geelong)
Credit point(s):1
EFTSL value:0.125
Unit Chair:Trimester 1: Garth Stephenson
Prerequisite:

HMM101 or HMM201

Corequisite:

Nil

Incompatible with:

Nil

Typical study commitment:

Students will on average spend 150 hours over the teaching period undertaking the teaching, learning and assessment activities for this unit.

Scheduled learning activities - campus:

1 x 1 hour online live class per week
2 x 1 hour classes per week- online H5P interactive modules
1 x 2 hour workshop per week - Campus based

Content

This unit provides a comprehensive overview of the business of medical biotechnology, including innovation management, funding, and the regulatory framework relevant to the industry. It will also explore risk management, and the societal and ethical issues pertinent to medical biotechnology in real-world scenarios.

ULO These are the Learning Outcomes (ULO) for this unit. At the completion of this unit, successful students can: Deakin Graduate Learning Outcomes

ULO1

Analyse the key principles of innovation and operational management of medical biotechnology.

GLO1: Discipline-specific knowledge and capabilities

ULO2

Evaluate the general business strategies and marketing concepts of medical biotechnology and how funding for medical biotechnology is secured.

GLO2: Communication

ULO3

Detail key regulatory and legal issues in medical biotechnology, including intellectual property, biopatenting, licencing and registration of therapeutics.

GLO3: Digital literacy
GLO8: Global citizenship

ULO4

Discuss the social and ethical aspects of medical and pharmaceutical biotechnology.

GLO4: Critical thinking
GLO8: Global citizenship

ULO5

Apply the principles of risk management in a medical biotechnology context.

GLO5: Problem solving

ULO6

Critically analyse and evaluate developments in medical and pharmaceutical biotechnology in industries, research institutions and big pharma.

GLO6: Self-management
GLO7: Teamwork
GLO8: Global citizenship

Assessment

Trimester 1:
Assessment description Student output Grading and weighting
(% total mark for unit)		 Indicative due week
Assessment 1: Mid-trimester test 45 minutes 20%
  • Week 6
Assessment 2: Poster with recorded presentation Equivalent to 1200 - 1500 words 30%
  • Week 8
Assessment 3: Online examination 2 hours 40%
  • Examination period
Assessment 4: Weekly seminar questionnaire Short answer or multiple-choice questions 10%
  • Weekly

The assessment due weeks provided may change. The Unit Chair will clarify the exact assessment requirements, including the due date, at the start of the teaching period.

Learning Resource

There is no prescribed text. Unit materials are provided via the unit site. This includes unit topic readings and references to further information.

Unit Fee Information

Click on the fee link below which describes you: